This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

Clinical Trials

/Clinical Trials

Lysogene MPS IIIA Clinical Trial Update

MPS IIIA is predominantly a central nervous system disease causing cognitive disability, progressive loss of acquired skills, behavioral and sleep disturbance. LYS-SAF302 is a gene therapy intended to deliver a functional copy of the SGSH gene to the brain. This is a phase 2-3 study to assess the efficacy in improving or stabilizing the neurodevelopmental state [...]

Clinical trial for genome editing treatment in MPS I and MPS II announced

"Patients with MPS I and MPS II have very few treatment options, and we are excited to expand access to our clinical trials to the U.K.," said Dr. Edward Conner, Chief Medical Officer at Sangamo. "We are pleased with the MHRA's rapid action on our CTA applications and to be working closely with them to advance [...]

Regenxbio receives FDA fast track designation for RGX-121 gene therapy for the treatment of MPS II

May 2, 2018 at 7:00 AM EDT -- Novel, one-time, direct-to-CNS investigational treatment for MPS II designed to prevent the progression of cognitive deficits-- Phase I/II clinical trial expected to enroll children with MPS II-- Expect to initiate patient recruitment and dosing in mid-2018 ROCKVILLE, Md., May 2, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a [...]

Pivotal phase gene transfer clinical trial for Mucopolysaccharidosis Type IIIA delivering LYS-SAF302

Pivotal phase gene transfer clinical trial for Mucopolysaccharidosis Type IIIA delivering LYS-SAF302 What is the purpose of this study? Lysogene is preparing a pivotal phase 2-3 clinical trial to assess the efficacy of direct to CNS delivery of LYS-SAF302 in improving or stabilizing the neurodevelopmental status of MPS IIIA patients. The trial will start in the [...]